Objective: To better understand postoperative opioid use after dermatologic surgery.Design: Prospective observational study.Setting: Academic dermatology department. Patients:The study included 212 adults (1) who were undergoing a single skin excision (including Mohs micrographic surgery), (2) who consented to participate, and (3) who were able to be reached by telephone on postoperative day 3 or 4. Patients who did not meet these criteria and those referred to another physician for further surgical treatment or repair were excluded. Main Outcome Measures:The study examined (1) the incidence of opioid prescription after dermatologic surgery, (2) the percentage of prescribed opioid pain medications used in the postoperative period, and (3) patient and surgical characteristics associated with opioid pain medication prescription and use.Results: Opioids were prescribed to 72 of the 212 patients (34%). Twenty-five of the 72 patients (35%) who were prescribed opioids did not use them. Forty-nine of 57 patients (86%) who filled an opioid prescription had leftover pills, and 26 of the 49 patients (53%) planned to keep them. Only maximum pain score was significantly associated with opioid use.Conclusions: Opioids were overprescribed after dermatologic surgery. Patients who had leftover opioids did not dispose of them properly, which could lead to potential misuse and abuse.

The retrospective review suggests that opioid prescribing is predicted by characteristics of the surgery (i.e., size, defect repair type, and anatomic location) and characteristics of the surgeon (i.e., age, sex, and practice location) with significant heterogeneity in prescribing habits. The national survey results raise the possibility that patients might not take all prescribed opioid pills after dermatologic surgery. Further investigation is warranted to determine how patients are actually using prescription pain pills to balance pain control with patient safety.

Increased fetal mortality and congenital malformation were induced in mice by Ca-DTPA, a chelate widely used for the removal of internally deposited plutonium in human beings. Mated C57BL/Do female mice were given five daily injections of 720-2,880 mumol/kg Ca-DTPA during early, mid, or late gestation. Damage probably occurred as a result of the depletion by Ca-DTPA of zinc and manganese, trace elements essential to growth and development. By extension, it seems likely that Ca-DTPA could damage human fetuses. A much safer chelate, Zn-DTPA, is recommended for the treatment of accidental plutonium contamination.

No abstract

No abstract